BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yamano M, Fujii H, Takagaki T, Kadowaki N, Watanabe H, Shirai T. Genetic Progression and Divergence in Pancreatic Carcinoma. Am J Pathol. 2000;156:2123-2133. [PMID: 10854233 DOI: 10.1016/s0002-9440(10)65083-3] [Cited by in Crossref: 106] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Wilentz RE, Argani P, Hruban RH. Loss of heterozygosity or intragenic mutation, which comes first? Am J Pathol 2001;158:1561-3. [PMID: 11337351 DOI: 10.1016/S0002-9440(10)64109-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
2 Hartel M, Narla G, Wente MN, Giese NA, Martignoni ME, Martignetti JA, Friess H, Friedman SL. Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer. Eur J Cancer 2008;44:1895-903. [PMID: 18691883 DOI: 10.1016/j.ejca.2008.06.030] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
3 Sy MS, Li C, Yu S, Xin W. The fatal attraction between pro-prion and filamin A: prion as a marker in human cancers. Biomark Med 2010;4:453-64. [PMID: 20550479 DOI: 10.2217/bmm.10.14] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kong X, Li L, Li Z, Xie K. Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications. Cytokine Growth Factor Rev 2012;23:343-56. [PMID: 22749856 DOI: 10.1016/j.cytogfr.2012.06.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
5 Lüttges J, Galehdari H, Bröcker V, Schwarte-Waldhoff I, Henne-Bruns D, Klöppel G, Schmiegel W, Hahn SA. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol 2001;158:1677-83. [PMID: 11337365 DOI: 10.1016/S0002-9440(10)64123-5] [Cited by in Crossref: 161] [Cited by in F6Publishing: 54] [Article Influence: 7.7] [Reference Citation Analysis]
6 Pogue-Geile KL, Chen R, Bronner MP, Crnogorac-Jurcevic T, Moyes KW, Dowen S, Otey CA, Crispin DA, George RD, Whitcomb DC. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med. 2006;3:e516. [PMID: 17194196 DOI: 10.1371/journal.pmed.0030516] [Cited by in Crossref: 135] [Cited by in F6Publishing: 128] [Article Influence: 9.0] [Reference Citation Analysis]
7 Franko J, Krasinskas AM, Nikiforova MN, Zarnescu NO, Lee KK, Hughes SJ, Bartlett DL, Zeh HJ, Moser AJ. Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2008;12:1664-1672; discussion 1672-1673. [PMID: 18677542 DOI: 10.1007/s11605-008-0577-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
8 Feldmann G, Beaty R, Hruban RH, Maitra A. Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg. 2007;14:224-232. [PMID: 17520196 DOI: 10.1007/s00534-006-1166-5] [Cited by in Crossref: 149] [Cited by in F6Publishing: 131] [Article Influence: 9.9] [Reference Citation Analysis]
9 Fujita Y, Kitago M, Masugi Y, Itano O, Shinoda M, Abe Y, Hibi T, Yagi H, Fujii-Nishimura Y, Sakamoto M, Kitagawa Y. Two cases of pancreatic ductal adenocarcinoma with intrapancreatic metastasis. World J Gastroenterol 2016; 22(41): 9222-9228 [PMID: 27895409 DOI: 10.3748/wjg.v22.i41.9222] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
10 Zammarchi F, Morelli M, Menicagli M, Di Cristofano C, Zavaglia K, Paolucci A, Campani D, Aretini P, Boggi U, Mosca F, Cavazzana A, Cartegni L, Bevilacqua G, Mazzanti CM. KLF4 is a novel candidate tumor suppressor gene in pancreatic ductal carcinoma. Am J Pathol 2011;178:361-72. [PMID: 21224073 DOI: 10.1016/j.ajpath.2010.11.021] [Cited by in Crossref: 52] [Cited by in F6Publishing: 59] [Article Influence: 4.3] [Reference Citation Analysis]
11 Howes N, Neoptolemos JP. Risk of pancreatic ductal adenocarcinoma in chronic pancreatitis. Gut. 2002;51:765-766. [PMID: 12427771 DOI: 10.1136/gut.51.6.765] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
12 Lim CS, Im K, Lee DS, Kwon W, Kim JR, Han Y, Kim SW, Jang JY. The Implication of Cytogenetic Alterations in Pancreatic Ductal Adenocarcinoma and Intraductal Papillary Mucinous Neoplasm Identified by Fluorescence In Situ Hybridization and Their Potential Diagnostic Utility. Gut Liver 2020;14:509-20. [PMID: 31533396 DOI: 10.5009/gnl19087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Layfield LJ, Ehya H, Filie AC, Hruban RH, Jhala N, Joseph L, Vielh P, Pitman MB;  Papanicolaou Society of Cytopathology. Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: the Papanicolaou Society of Cytopathology guidelines for pancreatobiliary cytology. Diagn Cytopathol. 2014;42:351-362. [PMID: 24639398 DOI: 10.1002/dc.23093] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 6.6] [Reference Citation Analysis]
14 Hruban RH, Wilentz RE, Kern SE. Genetic progression in the pancreatic ducts. Am J Pathol. 2000;156:1821-1825. [PMID: 10854204 DOI: 10.1016/s0002-9440(10)65054-7] [Cited by in Crossref: 252] [Cited by in F6Publishing: 105] [Article Influence: 11.5] [Reference Citation Analysis]
15 Pour PM, Pandey KK, Batra SK. What is the origin of pancreatic adenocarcinoma? Mol Cancer 2003;2:13. [PMID: 12636873 DOI: 10.1186/1476-4598-2-13] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 2.3] [Reference Citation Analysis]
16 Lüttges J, Klöppel G. [Pancreatic ductal adenocarcinoma and its precursors]. Pathologe 2005;26:12-7. [PMID: 15630571 DOI: 10.1007/s00292-004-0735-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
17 Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, DePinho RA. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003;17:3112-3126. [PMID: 14681207 DOI: 10.1101/gad.1158703] [Cited by in Crossref: 698] [Cited by in F6Publishing: 648] [Article Influence: 36.7] [Reference Citation Analysis]
18 Feldmann G, Maitra A. Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts. J Mol Diagn 2008;10:111-22. [PMID: 18258927 DOI: 10.2353/jmoldx.2008.070115] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
19 Roife D, Kang Y, Wang L, Fang B, Swisher SG, Gershenwald JE, Pretzsch S, Dinney CP, Katz MHG, Fleming JB. Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. Surgery 2017;161:1246-54. [PMID: 28081955 DOI: 10.1016/j.surg.2016.11.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
20 Yonezawa S, Higashi M, Yamada N, Goto M. Precursor lesions of pancreatic cancer. Gut Liver. 2008;2:137-154. [PMID: 20485640 DOI: 10.5009/gnl.2008.2.3.137] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 3.1] [Reference Citation Analysis]
21 Kong D, Nishino N, Shibusawa M, Kusano M. Establishment and characterization of a new cell line (SPH) derived from a pancreatic ductal adenocarcinoma. Pancreas 2007;35:188-9. [PMID: 17632328 DOI: 10.1097/01.mpa.0000250140.18015.9a] [Reference Citation Analysis]
22 Roe JS, Hwang CI, Somerville TDD, Milazzo JP, Lee EJ, Da Silva B, Maiorino L, Tiriac H, Young CM, Miyabayashi K, Filippini D, Creighton B, Burkhart RA, Buscaglia JM, Kim EJ, Grem JL, Lazenby AJ, Grunkemeyer JA, Hollingsworth MA, Grandgenett PM, Egeblad M, Park Y, Tuveson DA, Vakoc CR. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell 2017;170:875-888.e20. [PMID: 28757253 DOI: 10.1016/j.cell.2017.07.007] [Cited by in Crossref: 182] [Cited by in F6Publishing: 170] [Article Influence: 36.4] [Reference Citation Analysis]
23 Büchler P, Reber HA, Tomlinson JS, Hankinson O, Kallifatidis G, Friess H, Herr I, Hines OJ. Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer. Neoplasia 2009;11:196-206. [PMID: 19177204 DOI: 10.1593/neo.08734] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
24 Feldmann G, Rauenzahn S, Maitra A. In vitro models of pancreatic cancer for translational oncology research. Expert Opin Drug Discov 2009;4:429-43. [PMID: 20160967 DOI: 10.1517/17460440902821657] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
25 Cai JC, Liu D, Liu KH, Zhang HP, Zhong S, Xia NS. Microsatellite alterations in phenotypically normal esophageal squamous epithelium and metaplasia-dysplasia-adenocarcinoma sequence. World J Gastroenterol 2008; 14(25): 4070-4076 [PMID: 18609693 DOI: 10.3748/wjg.14.4070] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
26 Bhat K, Wang F, Ma Q, Li Q, Mallik S, Hsieh TC, Wu E. Advances in biomarker research for pancreatic cancer. Curr Pharm Des 2012;18:2439-51. [PMID: 22372502 DOI: 10.2174/13816128112092439] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 4.7] [Reference Citation Analysis]
27 Akerele CE, Rybalova I, Kaufman HL, Mani S. Current approaches to novel therapeutics in pancreatic cancer. Invest New Drugs 2003;21:113-29. [PMID: 12795537 DOI: 10.1023/a:1022936914328] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
28 Wang L, Tsutsumi S, Kawaguchi T, Nagasaki K, Tatsuno K, Yamamoto S, Sang F, Sonoda K, Sugawara M, Saiura A, Hirono S, Yamaue H, Miki Y, Isomura M, Totoki Y, Nagae G, Isagawa T, Ueda H, Murayama-Hosokawa S, Shibata T, Sakamoto H, Kanai Y, Kaneda A, Noda T, Aburatani H. Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. Genome Res 2012;22:208-19. [PMID: 22156295 DOI: 10.1101/gr.123109.111] [Cited by in Crossref: 83] [Cited by in F6Publishing: 77] [Article Influence: 7.5] [Reference Citation Analysis]
29 Paramythiotis D, Kleeff J, Schmidt J, Büchler MW, Friess H. Detection of oncogenes in chronic pancreatitis. HPB (Oxford) 2003;5:214-25. [PMID: 18332990 DOI: 10.1080/13651820310017804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
30 Layfield LJ, Ehya H, Filie AC, Hruban RH, Jhala N, Joseph L, Vielh P, Pitman MB. Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: The Papanicolaou Society of Cytopathology Guidelines. Cytojournal. 2014;11:4. [PMID: 25191518 DOI: 10.4103/1742-6413.133352] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
31 Löhr M, Klöppel G, Maisonneuve P, Lowenfels AB, Lüttges J. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 2005;7:17-23. [PMID: 15720814 DOI: 10.1593/neo.04445] [Cited by in Crossref: 209] [Cited by in F6Publishing: 190] [Article Influence: 12.3] [Reference Citation Analysis]
32 Jiang Z, Song J, Qi F, Xiao A, An X, Liu NA, Zhu Z, Zhang B, Lin S. Exdpf is a key regulator of exocrine pancreas development controlled by retinoic acid and ptf1a in zebrafish. PLoS Biol 2008;6:e293. [PMID: 19067490 DOI: 10.1371/journal.pbio.0060293] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
33 Vorvis C, Hatziapostolou M, Mahurkar-Joshi S, Koutsioumpa M, Williams J, Donahue TR, Poultsides GA, Eibl G, Iliopoulos D. Transcriptomic and CRISPR/Cas9 technologies reveal FOXA2 as a tumor suppressor gene in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 2016;310:G1124-37. [PMID: 27151939 DOI: 10.1152/ajpgi.00035.2016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
34 Krop IE, Sgroi D, Porter DA, Lunetta KL, LeVangie R, Seth P, Kaelin CM, Rhei E, Bosenberg M, Schnitt S, Marks JR, Pagon Z, Belina D, Razumovic J, Polyak K. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci U S A 2001;98:9796-801. [PMID: 11481438 DOI: 10.1073/pnas.171138398] [Cited by in Crossref: 91] [Cited by in F6Publishing: 80] [Article Influence: 4.3] [Reference Citation Analysis]
35 Roca R, Kypta RM, Vivanco Md. Loss of p16INK4a results in increased glucocorticoid receptor activity during fibrosarcoma development. Proc Natl Acad Sci U S A 2003;100:3113-8. [PMID: 12624188 DOI: 10.1073/pnas.0634912100] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
36 Saif MW, Karapanagiotou L, Syrigos K. Genetic alterations in pancreatic cancer. World J Gastroenterol 2007; 13(33): 4423-4430 [PMID: 17724796 DOI: 10.3748/wjg.v13.i33.4423] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
37 Sy MS, Li C, Yu S, Xin W. The fatal attraction between pro-prion and filamin A: prion as a marker in human cancers. Biomark Med 2010;4:453-64. [PMID: 20550479 DOI: 10.2217/bmm.10.14] [Reference Citation Analysis]
38 Klöppel G, Lüttges J. The pathology of ductal-type pancreatic carcinomas and pancreatic intraepithelial neoplasia: insights for clinicians. Curr Gastroenterol Rep 2004;6:111-8. [PMID: 15191688 DOI: 10.1007/s11894-004-0037-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
39 Xie D, Xie K. Pancreatic cancer stromal biology and therapy. Genes Dis. 2015;2:133-143. [PMID: 26114155 DOI: 10.1016/j.gendis.2015.01.002] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 10.9] [Reference Citation Analysis]